Belite Bio - Innovation Showcase at Ophthalmology Innovation Summit @ ASRS 2019 скачать в хорошем качестве

Belite Bio - Innovation Showcase at Ophthalmology Innovation Summit @ ASRS 2019

Irene Wang, COO speaks for Belite Bio during the Innovative Showcase at OIS@ASRS 2019. REGISTER for our next ophthalmology conference today http://bit.ly/2yFA6cv. Irene Wang, co-founder and COO, says Belite Bio has the first in class oral therapeutics for macular degeneration, targeting RBP4 (retinal binding protein 4), which is a major vitamin A delivery pathway. A phase 1 clinical trial is expected to be completed by the end of September 2019. The company’s lead asset is LBS-008, or Tinlarebant, an oral therapeutic for macular degeneration. The targeted indications are Stargardt disease, initially, and later, dry AMD. Belite Bio has received rare pediatric disease designation and orphan disease designation in the U.S. and E.U. for Stargardt disease. The mechanism of action is designed to address the problem of A2E, a cytotoxic compound that causes photoreceptor degeneration, and the solution is to block the major pathway of vitamin A delivery into the visual cycle, by blocking RBP4 with their RBP4 antagonist, to control the amount of vitamin A delivered. Pre-clinical studies show A2E reduction of 80 percent in the treatment group, and the researchers were able to rescue photoreceptors from degeneration. This presentation takes place at OIS@ASRS at the Ritz-Carlton in Chicago on July 25, 2019. WEBSITE https://ois.net FOLLOW Ophthalmology Innovation Summit On Social Media: ► Facebook:   / ois.net   ► Twitter:   / oistweets   JOIN Our Group For Ophthalmology Innovation & Investment On LinkedIn   / 2189664   SUBSCRIBE To Our Weekly OIS Newsletter http://bit.ly/2yFOXUt VIEW Our Past Ophthalmology Event Conferences: http://bit.ly/2yJ4Qts REGISTER For Our Next Conference: http://bit.ly/2yFA6cv #OIS #Ophthalmology #Healthcare _________________________________________________________________ About OIS Ophthalmology Innovation Summit, or OIS for short, facilitates meaningful interactions and the exchange of information between clinical, capital, and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs. The Ophthalmology Innovation Summit programs are presented annually by Healthegy, Inc. as affiliate meetings with American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), Southeastern Congress of Optometry (SECO), and American Society of Retina Specialists (ASRS). ____________________________________________________________________ Healthegy also is the producer of Aesthetics Innovation Summit (AIS), which unites the clinical, corporate and capital leaders to facilitate the exchange of insights on emerging trends while showcasing exciting new drugs, devices, and technologies for the aesthetics market which is projected to double by 2025. ► Website: https://attendais.com ► Facebook:   / aestheticsinnovation   ► Instagram:   / ais_summit   ► Twitter:   / ais_summit   ► Healthegy Website: https://healthegy.com